Drug-laboratory interaction between beta-lactam antibiotics and the galactomannan antigen test used to detect mould infections.
Several studies have demonstrated that piperacillin/tazobactam produces a false-positive result for the galactomannan antigen test. However, the most recent literature has demonstrated that this interaction is no longer a concern. There is little information regarding the drug-laboratory interaction with the generics of piperacillin/tazobactam or other broad-spectrum beta-lactams, such as ceftaroline, doripenem, imipenem/cilastatin, and meropenem. The purpose of this study was to determine if a drug-laboratory interaction exists with these antibiotics. Tests showed that one lot of imipenem/cilastatin by Hospira Healthcare India Private Limited produced a false-positive result for the galactomannan antigen test. All other medications tested, including piperacillin/tazobactam from seven manufacturers and imipenem/cilastatin by Hospira Inc., did not produce positive results. Since the reason for this drug-laboratory interaction with imipenem/cilastatin is unknown, more studies are needed to further investigate this interaction. Providers also should be educated of these findings: no drug-laboratory interaction with piperacillin/tazobactam and a possible drug-laboratory interaction with imipenem/cilastatin (Hospira Healthcare India Private Limited).
Department of Pharmacy, University of Mississippi Medical Center, Jackson, United States.
Kristin A
KA
Otting
Department of Pharmacy Practice, School of Pharmacy, University of Mississippi, Jackson, United States; School of Medicine, University of Mississippi Medical Center, Jackson, United States. Electronic address: kstover@umc.edu.
Kayla R
KR
Stover
School of Medicine, University of Mississippi Medical Center, Jackson, United States; Department of Pharmacy, St. Dominic-Jackson Memorial Hospital, Jackson, United States.
John D
JD
Cleary
D000946:Antigens, Fungal / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects / Q000276:immunology*; D004347:Drug Interactions; D016568:Drugs, Generic / Q000494:pharmacology*; D005189:False Positive Reactions; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D008351:Mannans / Q000276:immunology*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D047090:beta-Lactams / Q000494:pharmacology*
D000946:Antigens, Fungal; D016568:Drugs, Generic; D008351:Mannans; D047090:beta-Lactams; C012990:galactomannan; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; D005690:Galactose
Beta-lactams; Drug interaction; Galactomannan; Piperacillin–tazobactam